McKesson, CD&R to Buy Option Care Health in $5.8 Billion Deal

McKesson Corp. and Clayton Dubilier & Rice will acquire Option Care Health Inc. for $5.8 billion. McKesson will invest $1.4 billion for a 49% stake. Option Care shares surged 20% overnight, halted before trading. The deal, at a 37% premium, is expected to close in 2027.

Original reporting
Published Oct 6, 2026, 12:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 12:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$MCK
Neutral
high confidence
Mentioned
$MCK · $OPCH
Relevance
9/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$MCKNeutralHigh
01

Why it matters

The deal adds a strategic asset for McKesson while providing Option Care shareholders a premium exit.

02

Market read

The announcement drives immediate price moves and signals continued consolidation in the healthcare services sector.

03

What to watch

Regulatory approval risk and integration challenges could delay value realization.

Relevance 9/10Novelty 9/10Timing: today

Background

The acquisition expands McKesson's footprint into the medical infusion market, a growing segment of specialty care.

Company-level read

Ticker impact

$MCKNeutralHigh confidence
Context

McKesson announced a $5.8B acquisition of Option Care Health, investing $1.4B for a 49% stake.

Expected impact

potential slight downside as investors price the $1.4B cash investment

Evidence & confidence

The deal size is material but the market typically reacts cautiously to large acquisitions that require significant capital.

$OPCHBullishHigh confidence
Context

Option Care Health shares were halted then surged >20% after the $5.8B acquisition announcement with a 37% premium.

Expected impact

upward pressure as the market prices in the 37% premium and deal completion

Evidence & confidence

The announced premium and immediate 20% jump indicate strong buyer enthusiasm; the deal is expected to close in H1 2027.

Market effects

Healthcare services consolidation may boost valuations of other infusion and specialty pharmacy providers.

U.S. healthcare M&A activity could see heightened investor interest.

Large U.S. healthcare deals influence global pharma and biotech investment sentiment.

Counterpoint

Some investors may view the cash outlay as overpaying, risking dilution of McKesson's balance sheet.

Key entities

  • McKesson Corp.

    U.S. healthcare services and distribution giant.

  • Option Care Health Inc.

    Provider of home and alternate site infusion services.

  • Clayton Dubilier & Rice

    PE firm taking majority ownership of Option Care.

Related articles

$MCKHighAI 8/10

Healthcare providers & services stocks Q3 results: Benchmarking McKesson

McKesson (MCK) reported Q3 revenue of $111B, up 7.6% YoY, beating estimates. LifeStance Health (LFST) saw 25.3% revenue growth, while Brookdale (BKD) reported a 12.4% decline. Elevance Health (ELV) and The Pennant Group (PNTG) also released Q3 results, with mixed outcomes. Sector revenues beat estimates by 2.2%, and stocks are up 4.4% on average since earnings.

$MCKMedAI 8/10

Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New Highs

McKesson (MCK), the largest U.S. pharmaceutical distributor, reported Q2 2027 revenue of $111B (up 8% YoY), driven by North American pharmaceuticals and GLP-1 distribution. Operating profit rose 13% to $1.9B, and adjusted EPS increased 18% to $11.68. The company raised full-year EPS guidance to up to $46.40, implying 19% growth. MCK shares are up 32% YTD, with strong institutional support and long-term growth trends.